Our Products

We concentrate on areas where there is a high unmet need and that offer the greatest potential to make a real difference in the lives of patients.
George A. Scangos, Ph.D., Chief Executive Officer
2011 was a significant year for our products. Our MS franchise demonstrated strong momentum. AVONEX global sales reached $2.7 billion, a 7 percent increase year over year. To support the continued revenue growth of AVONEX, we introduced the AVONEX PEN to Canada and markets throughout Europe, and in 2012 to the U.S., improving administration for patients and reinvigorating physician interest.

Global in-market sales of TYSABRI increased by 23 percent, and we hit key milestones that are important for unlocking the value of TYSABRI. The label was changed in the EU to include the presence of anti-JC virus (JCV) antibodies as a factor that increases the risk of a serious, but infrequent side effect known as progressive multifocal leukoencephalopathy (PML), and then subsequently in the U.S. in 2012. This change can help physicians and people with MS have more confidence in their treatment decisions when considering TYSABRI. Additionally, an assay to detect anti-­JCV antibodies, STRATIFY JCV, was made broadly available.

FAMPYRA (prolonged-­release fampridine tablets) — the first treatment that addresses the unmet need of walking improvement in adults with MS — launched outside the U.S., and RITUXAN continued to be a significant revenue stream.